OnKure Therapeutics, Inc. OKUR
OnKure Therapeutics, Inc. ("OnKure", "we", "us" or the "Company") is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases that are underserved by available therapies. Using a structure-based drug design platform, we are committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to achieve optimal efficacy and tolerability by selectively targeting specific mutations shown to be key drivers of cancer and other diseases. By selectively sparing the wild-type enzyme and preferentially targeting the mutated form of the protein, which is oncogenic and drives disease processes in both cancer and vascular overgrowth syndromes, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that arises from non-selective inhibition of the non-mutated (or wild-type) version of the protein. We work under the principle that inhibiting target proteins with specific mutations instead of wild-type variants should enable precise patient selection that will, in turn, improve the probability of clinical success. We designed our current product candidates utilizing disciplined medicinal chemistry, x-ray crystallography and computational chemistry to inhibit specified mutated versions of phosphoinositide 3-kinase alpha ("PI3Kα"), a key disease creating gene.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — | — | — |
| R&D | $48.3M | $43.8M | $32.1M | $37.7M | $28.2M | $15.9M | — |
| SG&A | $14.7M | $10.6M | $4.8M | $16.1M | $11.6M | $3.6M | — |
| Total operating expenses | $63.0M | $54.4M | $36.9M | $53.8M | $39.8M | $19.6M | — |
| Operating income | -$63.0M | -$54.4M | -$36.9M | -$53.8M | -$39.8M | -$19.6M | — |
| Interest expense | $3.4M | $1.7M | $1.6M | — | — | — | — |
| Pre-tax income | -$59.5M | -$52.7M | -$77.4M | -$52.0M | -$39.8M | -$19.5M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$59.5M | -$52.7M | -$35.3M | -$52.0M | -$39.8M | -$19.5M | — |
| EPS, basic | -4.40 | -15.28 | -124.41 | -2.12 | -2.19 | -9.60 | — |
| EPS, diluted | -4.40 | -15.28 | -124.41 | -2.12 | -2.19 | -9.60 | — |
| Shares, diluted (wtd. avg.) | 13.5M | 3.4M | 283,817 | 24.5M | 18.1M | 2.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $59.0M | $110.8M | $29.9M | $11.5M | $124.7M | $53.6M | $17.5M |
| Short-term investments | — | — | $75.3M | $81.2M | $23.0M | — | — |
| Total current assets | $60.8M | $113.0M | $33.8M | $106.4M | $153.7M | $55.0M | — |
| Property, plant and equipment | $618.0K | $1.0M | $1.4M | $453.0K | $212.0K | $69.0K | — |
| Total assets | $62.1M | $114.9M | $35.7M | $108.2M | $154.0M | $55.2M | — |
| Accounts payable | $1.4M | $3.0M | $3.4M | $1.9M | $2.0M | $908.0K | — |
| Total current liabilities | $5.9M | $10.5M | $7.3M | $7.1M | $6.2M | $4.6M | — |
| Total liabilities | $5.9M | $11.1M | $7.8M | $8.2M | $6.8M | $4.6M | — |
| Retained earnings | -$214.2M | -$154.7M | -$102.1M | -$136.7M | -$84.7M | -$45.0M | — |
| Total equity | $56.2M | $103.8M | -$101.8M | -$54.4M | $147.2M | -$42.1M | -$23.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$51.8M | -$51.1M | -$34.5M | -$47.4M | -$38.0M | -$18.5M | — |
| Depreciation and amortisation | $447.0K | $459.0K | $417.0K | $88.0K | $50.0K | $37.0K | — |
| Stock-based compensation | $11.6M | $4.5M | $199.0K | $4.3M | $3.9M | $393.0K | — |
| Capital expenditure | $46.0K | $52.0K | $246.0K | $346.0K | $198.0K | $24.0K | — |
| Investing cash flow | -$46.0K | $15.9M | -$246.0K | -$57.8M | -$23.4M | $7.4M | — |
| Financing cash flow | $163.0K | $116.1M | $53.1M | $471.0K | $132.4M | $47.3M | — |
| Buybacks | — | — | $4.4M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-104147.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$19.5M | -$39.8M | -$52.0M | -$35.3M | -$52.7M | -$59.5M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |